Sign In
Buy CADL
$8.80
+0.380 (+4.51%)
At Close: Jun 03, 2026
CADL Up as FDA Grants RMAT Status to CAN-2409 in Prostate Cancer
11:50am, Thursday, 29'th May 2025
Candel stock rises as FDA grants RMAT tag to CAN-2409 after phase III success in prostate cancer. BLA submission is planned at the end of 2026.
Candel Therapeutics get FDA's RMAT designation for prostate cancer therapy
09:34am, Wednesday, 28'th May 2025
Candel Therapeutics Inc (NASDAQ:CADL) said on Wednesday the US Food and Drug Administration has granted Regenerative Medicine Advanced Therapy (RMAT) designation to its lead immunotherapy candidate, C
Candel Therapeutics Receives FDA Regenerative Medicine Advanced Therapy Designation for CAN-2409 for the Treatment of Prostate Cancer
08:05am, Wednesday, 28'th May 2025
NEEDHAM, Mass., May 28, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biologica
NEEDHAM, Mass., May 27, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biologica
Candel Therapeutics to present Phase 3 prostate cancer trial data at ASCO 2025
08:41am, Friday, 23'rd May 2025
Candel Therapeutics Inc (NASDAQ:CADL) announced that it will present results from its positive Phase 3 trial of CAN-2409 in patients with intermediate-to-high-risk localized prostate cancer at the 202
Candel Therapeutics Presents Positive Phase 3 CAN-2409 Results in Localized Prostate Cancer at ASCO 2025
05:05pm, Thursday, 22'nd May 2025
NEEDHAM, Mass., May 22, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biologica
Best Momentum Stocks to Buy for May 19th
11:01am, Monday, 19'th May 2025
CADL, HMN and MAG made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on May 19, 2025.
New Strong Buy Stocks for May 19th
08:51am, Monday, 19'th May 2025
SUBCY, MAG, KARO, CADL and BPOP have been added to the Zacks Rank #1 (Strong Buy) List on May 19, 2025.
Wall Street Analysts Predict a 310.96% Upside in Candel Therapeutics (CADL): Here's What You Should Know
11:01am, Friday, 16'th May 2025
The mean of analysts' price targets for Candel Therapeutics (CADL) points to a 311% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement amo
Candel Therapeutics posts Q1 profit, eyes 2026 BLA submission for prostate cancer drug
09:03am, Tuesday, 13'th May 2025
Candel Therapeutics Inc (NASDAQ:CADL) reported a quarterly profit and said it remains on track to submit a biologics license application (BLA) in late 2026 for its lead cancer therapy, CAN-2409, aimed
Candel Therapeutics Reports First Quarter 2025 Financial Results and Recent Corporate Highlights
08:05am, Tuesday, 13'th May 2025
NEEDHAM, Mass., May 13, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biologica
Candel Therapeutics to Present at Upcoming Investor Conferences
08:05am, Tuesday, 06'th May 2025
NEEDHAM, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biologica
Candel Therapeutics Announces Oral Presentation of Positive Phase 3 CAN-2409 Results in Localized Prostate Cancer at ASCO 2025
04:05pm, Wednesday, 23'rd Apr 2025
NEEDHAM, Mass., April 23, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biologi
Candel Therapeutics reveals new data showing better outcomes for glioma patients using CAN-2409
09:46am, Tuesday, 01'st Apr 2025
Candel Therapeutics Inc (NASDAQ:CADL) shared promising results from a Phase 1b clinical trial testing its experimental cancer therapy, CAN-2409, in patients with newly diagnosed high-grade glioma—a
Data published in Neuro-Oncology demonstrate promising safety profile and potential survival benefit when combining CAN-2409 and nivolumab with standard of care Data published in Neuro-Oncology demons
